Rating: Cautious Buy | Target Price: HKD 8.0–10.5 | Current Price: HKD 6.27 (close on 2026-11-20) | Margin of Safety: 27.6% (based on the lower bound of the base-case fair value) | Time Horizon: 12 months
Huayan Robotics is China's No. 2 collaborative robot (cobot) vendor by revenue (Frost & Sullivan, 2024), differentiated by its dual positioning in "complete robots + core motion components" and a rare European industrial channel. After listing at HKD 17.00 on 2026-03-30, the stock has fallen deeply below its IPO price (current price -63% vs. offer price, -74% vs. 52-week high). The immediate trigger was the unlock of cornerstone and pre-IPO shareholders on 9/29 combined with stalled H1 2026 results (revenue +0.6%, adjusted profit turning to a loss). This report judges that: of the current HKD 3.493 billion market cap, net cash accounts for roughly 55% (HKD 3.47 per share); excluding cash, EV is only about 3.4x TTM revenue, indicating the market has deeply discounted the sell-side's doubling path for 2027. The discount contains both a reasonable component—the unlock overhang and unverified orders—and a portion not yet priced in: evidence of H2 order catch-up (inventory +69.4% stock-up, management's "orders deferred to H2" commentary). An event-verification opportunity: cautious buy, but entry should wait for verification via the February 2027 profit warning and order announcements; key constraints are the unlock of roughly 51% of share capital on 2027-03-30, high customer and order concentration, and weak earnings and cash flow quality.
Key evidence
The cash floor is a real safety cushion: the company has no refinancing needs (at the H1 burn rate, cash runway is roughly 10 years), and in an extreme scenario the HKD 3.47 per share of net cash provides a liquidation reference. But three constraints must be acknowledged: first, about two-thirds of the RMB 1.644 billion is IPO net proceeds, whose use is contractually locked by the prospectus (R&D/expansion/overseas), and given cumulative losses the articles of association restrict dividends—the cash supports survival and investment capability, not distributable returns; second, the figure is as of 2026-06-30, and subsequent H2 operating consumption plus the executed HKD 23.08 million buyback will gradually erode it; third, "deep discount" claims require restraint—EV/TTM revenue of 3.4x is below HK-listed peers' PS (Dobot 8.2x, UBTech 9.4x), but peers are growing far faster (Dobot 2026H1 +106.6% vs. Huayan +0.6%), and a substantial portion of the discount is rational pricing of growth stagnation and the unlock overhang. This report's conclusion: the price is significantly below base-case fair value, but the undervaluation is "event-verification" type, not a steady-state mispricing.
Key evidence
Bull evidence chain: management explicitly stated in the interim report that orders were pushed to H2; inventory rose +69.4% from the start of the year to RMB 175.5 million (corroborating the stock-up); customer NEURA Robotics completed a Series C of up to USD 1.4 billion in June 2026 (post-money USD 7 billion, with NVIDIA/Bosch participating), ample funding for mass production. Bear evidence chain: the USD 100 million framework amount exists only in media reports with no corresponding voluntary announcement on HKEXnews, and with no minimum purchase volume or delivery timetable; in November BOCOM already cut 2026E revenue by 17% citing "delivery pace + safety certifications"; 2026H1 European revenue fell -67.1% YoY (Germany -77.3%). This thesis is the core source of this report's expectation gap and also the largest single uncertainty: whether the orders are "deferred" or "gone" will be settled by the February 2027 profit warning and the March annual report.
Key evidence
The first unlock wave on 9/29 (cornerstones ~8.1% + some pre-IPO shareholders, ~27.7% of share capital combined) has already created a real gap: the stock fell -13.4% in a single day the day before the unlock, and average daily turnover shrank from ~HKD 50.3 million to ~HKD 12 million in November. The next wave is bigger: the controlling shareholder's concert-party group holds roughly 280–320 million shares (~51%–57% of total share capital, estimated), whose 12-month lock-up expires on 2027-03-30, worth roughly HKD 1.77–2.0 billion at current prices—equivalent to about 148–166 trading days of current turnover. The company's RMB 200 million (~HKD 235 million) buyback mandate hedges only ~13% of the overhang, and as of 11/20 only ~10% (HKD 23.08 million) has been executed; the ESOP platform's 18.03 million-share full-circulation application is still under CSRC filing. In a market structure with thin liquidity, the unlock is the strongest constraint on valuation over the next 3–6 months; hedge watch items are buyback acceleration, controlling-shareholder lock-up extension, or a Han's Laser increased-holding announcement.
Key evidence
Three structural problems: ① the company's self-reported adjusted measure adds back in full the annually recurring share-based payments (the FY2023 add-back was 37x reported net profit), and FY2023's reported profit also relied on one-offs such as disposal gains, government grants, and tax credits; ② inventory turnover of 213–290 days and receivables of 107–129 days, with management itself admitting "cash is tied up for long periods in inventory and receivables"—OCF was deeply negative in years of high revenue growth; ③ of the 2026H1 adjusted loss of RMB 36.65 million, FX losses were RMB 31.37 million—ex-FX, core operations were roughly RMB -5.28 million, near breakeven—but the unhedged HKD fundraising means FX is a recurring swing item (every 3% RMB appreciation adds roughly another RMB 46 million in book losses), and it cannot simply be treated as one-off. Conclusion: book growth has not yet converted into cash; the valuation's safety cushion exists only at the balance sheet (net cash) layer, with no buffer at the earnings and cash flow layers.
Key evidence
The two measures must be juxtaposed: Sullivan, hired for the prospectus (revenue basis, 2024), gives "No. 2 in China," but independent agency GGII's 2025 unit-sales top five excludes Huayan—revenue includes components sold externally while unit sales count only complete robots; moreover, against 2025 industry unit sales +45.6%, the company's revenue grew only +24.6%, and just +0.6% in 2026H1—market share is likely under pressure. The differentiated assets are real: the only leading domestic cobot vendor selling core motion components externally (23.4% of 2024 revenue at 36.6% gross margin; frameless torque motors 53.9%); the ±50nm precision motion platform taps into the AI capex chain of optical modules/wafer inspection; ranked No. 2 on a 2025 overseas-expansion list. The material basis for the "picks-and-shovels" (humanoid robot components supplier) narrative exists, but 2026H1 components revenue fell -18.8% YoY, and commercialization is not yet confirmed by orders.
| Metric (RMB) | FY2022 | FY2023 | FY2024 | FY2025 | 2026H1 |
|---|---|---|---|---|---|
| Revenue (RMB million) | 109.4 | 175.4 | 310.4 | 386.9 | 174.1 |
| Revenue YoY | — | +60.2% | +77.0% | +24.6% | +0.6% |
| Net profit attributable to owners (RMB million) | -83.4 | 1.9 | 17.9 | -29.9 | -56.9 |
| Adjusted net profit (Non-IFRS, RMB million) | -70.5 | 71.5 | 17.9 | 25.7 | -36.7 |
| Gross margin | 13.7% | 28.6% | 34.3% | 37.6% | 32.3% |
| Net margin | -76.2% | 1.1% | 5.8% | -7.7% | -32.7% |
| Operating cash flow (RMB million) | -153.5 | -57.2 | +11.9 | — (9M2025: -18.3) | -78.4 |
| Free cash flow (RMB million) | — | — | — | — | ~-137.7 (incl. RMB 52.5 prepayment for Jiangmen property) |
| Cash + cash-like assets (RMB 100 million) | — | — | 1.20 | 1.78 (year-end) | 16.44 (2026-06-30) |
| Interest-bearing debt | — | — | — | — | ≈0 (breakdown not disclosed; debt-to-asset ratio 9%) |
| Debt-to-asset ratio | — | — | — | 22% (year-end) | 9% |
Note: The adjusted measure is the company's self-reported Non-IFRS (adding back share-based payments/listing expenses, etc.); its aggressiveness is discussed in Sections C4 and E4. FY2025 full-year OCF and per-year CapEx details could not be verified due to a local PDF parsing failure and are marked "—" without speculation.
Drivers of metric changes (items with YoY ≥ ±20%): ① FY2024 revenue +77.0%—the prospectus attributes this to "increased sales of E-series products to a major overseas European customer" (the customer is also a supplier and a former joint venture party, i.e., the NEURA group); ② FY2025 swing from profit to loss—company's original wording: "mainly due to listing expenses, share-based payments, and increased R&D expenses"; ③ 2026H1 net loss widened to RMB 56.90 million—selling expenses +48.5% (expanding the sales team and overseas promotion), FX losses of RMB 31.37 million (over 50% of the net loss), listing expenses of RMB 11.91 million; ④ 2026H1 European revenue -67.1%, Germany -77.3%—management attributes this to "the major European customer concentrating key projects and orders into H2"; ⑤ S-series ASP -31.8% YoY to RMB 56,400/unit in 9M2025—the company disclosed only a tiered pricing policy without separately explaining the decline; ⑥ cash-like assets 1.78→1.644 billion RMB—receipt of IPO proceeds.
Revenue of RMB 174 million, up only +0.6% YoY—a "growth stagnation" signal in the first report card post-listing: structurally, mainland China +39.5% (driven by complete cobots +8.3%), Europe -67.1%, Americas -57.9%—overseas revenue share plunged from 50.2% in FY2024 to about 12%. Gross margin 32.3% (-4.1pp YoY), reflecting the absence of high-margin overseas revenue and continued price competition. Net loss attributable to owners of RMB 56.90 million; adjusted net loss of RMB 36.65 million (vs. adjusted profit of RMB 10.53 million in the prior-year period); ex-FX, core operations were roughly RMB -5.28 million, near breakeven—the bulk of the loss is the FX book loss on HKD fundraising proceeds and listing expenses, but this precisely exposes a financial-management weakness: currency mismatch in fundraising with no hedging. Operating cash flow -RMB 78.42 million; inventory +69.4% to RMB 175.5 million (with RMB 5.4 million of write-downs already provisioned)—the inventory surge and management's "orders deferred to H2" explanation corroborate each other and are the core physical evidence for the H2 catch-up thesis. Versus expectations: there is no formal consensus (BOCOM International is the only active covering house); its 2026E revenue of RMB 506 million implies H2 needs RMB 332 million (+38% YoY); management's stance is the qualitative statement that "results are expected to be released rapidly in H2." This report's quick-review conclusion: the H1 statements themselves are "bad," but their informational value lies in cleanly pushing the verification point to February–March 2027.
Business model sketch: Asset-light, transactional product sales—complete cobots (E-series high-precision / S-series heavy-payload) plus external sales of core motion components (frameless torque motors, joint modules, precision motion platforms), mainly direct sales (93.8% direct in FY2024, of which system integrators accounted for 86.0%), distribution only 6.2%; OEM-style manufacturing at Foshan and Shenzhen bases, 2025 annualized capacity of 5,269 units at 73.9% utilization. Revenue is non-recurring (services only 0.3%–0.9% of revenue), pricing power is weak (ASPs of both series declining at an accelerating pace), but in-house components give it some cost initiative over both upstream (outsourced reducers/encoders) and downstream (integrator major customers).
Cash content of earnings test: OCF/net profit was -30.2 in FY2023 (marginal profit with large outflow), 0.67 in FY2024 (below the 0.8 warning line), and both negative in 2026H1 (ratio distorted); FCF in 2026H1 was about -RMB 138 million. Operating cash flow negative in four of five years plus inventory turnover of 213–290 days indicates a substantial portion of book revenue has been tied up in inventory and receivables—this is the quantitative foundation of thesis C4. On "recurring profitability": FY2025 reported net loss of RMB 29.90 million vs. adjusted +RMB 25.70 million, with the gap mainly from listing expenses and share-based payments; but the company's self-reported measure is itself loose (full SBC add-back), and this report uses "adjusted ex-FX, approximately -RMB 5.28 million (2026H1)" as the core operating measure.
Return on capital: Net profit negative in FY2025 and 2026H1, making ROIC distorted and unestimable; pre-IPO net assets were thin and post-IPO cash dominates net assets, so book ROE is not meaningful—existing materials are insufficient to judge the quality of capital returns; reassess after the return to profitability in 2027.
CapEx quality: No breakdown between maintenance and growth capEx is disclosed, so the maintenance investment level cannot be determined; of 2026H1 capEx of RMB 59.24 million, RMB 52.55 million was a prepayment for the Jiangmen property—expansion in nature, consistent with the prospectus commitment of "15% of proceeds for capacity expansion."
Moat and red flags: The moat comes from full-stack in-house motion control (238 patents, self-supplied components) and the European channel (50.2% overseas revenue in 2024; overseas gross margin above domestic); red flags include top-5 customer concentration of 60.6% (2024), the largest customer at 37.4% with a triple role as customer, supplier, and former JV partner, and a social insurance/housing fund contribution shortfall of RMB 10.90 million (as of 2025-09-30).
Consistency between words and deeds: To be verified, provisionally "Neutral." There are only two verifiable promise-delivery pairs: ① IPO proceeds received (RMB 1.644 billion in cash, 2026-06-30) — first step delivered, with prepayment for Jiangmen property indicating capacity expansion has begun; ② Share buyback plan announced 2026-10-02 (cap RMB 200 million, to be cancelled) — as of 11/20, executed on 7 consecutive trading days for 3.51 million shares / HK$23.08 million, in progress but at a moderate pace (~10% of quota). Key item to verify: the interim report statement that "European major customer orders are concentrated in the second half, with rapid earnings release expected in H2" — a similar H2-concentrated recognition occurred once before in 2025 (Q4-2025 single-quarter revenue of ~RMB 106 million); whether this materializes will directly define management credibility. No record of high-profile earnings guidance; style shows no signs of exaggeration.
Shareholder friendliness: Neutral to positive (constrained). Zero dividends during the track-record period (no short-term payout capacity due to cumulative losses and statutory reserve restrictions), but launching a cancellation-type buyback just 7 months after listing is a positive signal among newly listed HK stocks; cornerstone investors at IPO including Hillhouse HHLR, GF Fund, and Morgan Stanley (HK$770 million in aggregate) show institutional endorsement — however, Morgan Stanley's dual role as both sponsor and cornerstone reflects deep investment-bank entanglement, diluting its independence.
Risk signals: Related-party sales to the Han's Laser group of RMB 8.04 million (2026H1, 4.6% of revenue) and reliance on related-party property/leasing; Chairman Wang Guangneng also serving as General Manager (deviation from the Corporate Governance Code, disclosed); Han's Laser (13.57%) has emerged from lock-up, and its A-share parent's profit pressure creates sell-down incentives; rising balance of unpaid social security contributions.
| Segment | Revenue share (FY2024) | Gross margin (FY2024) | Latest developments |
|---|---|---|---|
| Complete cobot units (E+S series) | 75.9% | 35.2% (9M2025: 38.2%) | 2026H1 revenue RMB 133 million, +8.3%; E-series 9M25 ASP RMB 55,900 (-14.6%) |
| Core motion components | 23.4% | 36.6% (9M2025: 40.5%) | 2026H1 revenue RMB 40.26 million, -18.8%; frameless torque motor gross margin 53.9% |
| Services and others | 0.7% | — | Virtually no recurring revenue |
Estimating gross profit contribution by "revenue share × gross margin": complete units contribute roughly two-thirds, components roughly a quarter — complete units remain the profit mainstay, but the components' gross margin structure (frameless torque motors 53.9% > joint modules 40.9% > precision platforms 39.9%) is significantly better than the complete-unit side, where ASPs are suppressed by price wars, making it the direction for future gross margin upgrading. The largest gross margin divergence is geographic: Americas 55.2% vs Mainland China 30.6% (FY2024), a gap of ~25pp — overseas pricing is high while the domestic price war is brutal, which explains the direct -4.1pp hit to gross margin from the absence of overseas revenue in 2026H1. The single-core-business profile is clear; the company is effectively a "complete units + components" integrated manufacturer, and segment disclosure granularity is adequate.
Accounting red flags (ordered by severity): ① Aggressive Non-GAAP add-backs (High): FY2023 share-based payment of RMB 6.957 million fully added back; adjusted net profit of RMB 71.47 million vs reported net profit of RMB 1.90 million — a 37x amplification — SBC is a recurring labor cost every year; ② Earnings reliance on one-off items (Medium): FY2023 other income and gains of RMB 105.6 million (disposal of subsidiaries/JV + government grants), plus tax credits of RMB 41.44 million, were the main drivers of the swing to profit that year; ③ Abrupt change in inventory write-down provisioning (Medium): 2022 provision of RMB 14.12 million → 2023 plummeted to RMB 0.65 million (-96%), while inventory turnover remained as high as 290 days — adequacy of write-downs is questionable; ④ Abnormal effective tax rate (Medium): tax credits of RMB 41.44 million in 2023 vs only RMB 1.16 million in 2024; ⑤ Overlapping related-party roles (Medium): largest customer = supplier = former joint venture (NEURA group), with two-way dependence on revenue and procurement and questionable pricing independence; moreover, 2025 cash flow shows "loan repayment from Neura Robotics GmbH of RMB 19.19 million" — traces of customer financing; ⑥ Unpaid social security (Low): shortfall of RMB 10.90 million and rising balance.
Cross-period consistency: ① OCF vs net profit — negative in four of five years, with net profit positive only in 2024; management attributes this to "timing gaps in settlements with suppliers and customers" and working capital tied up in inventory and receivables, consistent across both periods; ② Europe/largest customer revenue — FY2023 RMB 31.20 million → FY2024 RMB 124.3 million (+299%) → 2026H1 -67.1% YoY, explosive surge and collapse; during the downturn the company gave no direct attribution (only "deployment shifted to H2"), and this cross-period explanation gap is the disclosure point we are least comfortable with in this report; ③ ASP — E/S series ASPs declining at an accelerating pace; the company discloses only a tiered pricing policy without explaining the magnitude of declines; ④ R&D expenses — plunged in FY2024 due to sale of the joint venture, then rebounded +18.5% in 2026H1; management's explanation is consistent. Disclosure cycle note: the company listed in 2026-03, with only one interim report post-listing; the track record covers three years + 9M2025, so a formal cross-period consistency assessment is constrained; the above judgments are based on the accountants' report in the prospectus and the interim report.
Current market data: Share price HK$6.27 (close 2026-11-20), total shares outstanding 557,066,580, market cap HK$3.493 billion (RMB 2.973 billion, at HK$1 = RMB 0.8513, 2026-11-21). The company listed on 2026-03-30, has been listed less than 1 year and is loss-making — PE and its percentile are meaningless (the 8-month window percentile of PB at 1.51x is also reference-only); PS/EV/S is the primary anchor: PS(2025A) 7.7x, PS(TTM) 7.7x, EV/S(TTM) 3.4x, EV/S(2026E, BOCOM) 2.6x, EV/S(2027E, BOCOM) 1.4x. Peer benchmarks:
(Dobot: 2026H1 revenue +106.6%, gross margin 47.4%, still loss-making; UBTech: humanoid complete-unit precedent, operating cash flow -RMB 750 million, burning cash for growth; Inovance: ~11% net margin, the ceiling for earnings quality; Estun/MOONS': low-end A-share anchors for complete units/motors. Huayan's headline PS is comparable to HK peers, but its EV/S after stripping out net cash is at the lowest tier of the group — the entire difference comes from its 55% cash ratio.)
Market-implied expectations: The current price implies a discount of ~39% to the only active sell-side anchor (BOCOM: HK$10.36). Reverse engineering must be cautious: BOCOM's 2027E revenue of ~RMB 980 million already embeds a European rebound (+94% vs 2026E); at the current price the corresponding EV/S is ~1.4x — the market applies a significant discount to "rebound materializing as scheduled." But back-solving from current market cap ÷ 5x PS to an "implied 2027E revenue of ~RMB 590 million" treats a sell-side multiple as fair value — a circular calculation this report does not make. A more defensible statement: the current price requires the market to believe "FY2026 revenue flat to slightly negative vs 2025, with a moderate recovery in 2027," while paying almost nothing for NEURA's ~RMB 240 million average annual framework volume and the humanoid components option; against reality — FY2023-25 revenue +60%/+77%/+25%, order deferrals corroborated by inventory build, and the customer having just raised USD 1.4 billion — this pricing is on the pessimistic side, though the discount partly reflects the looming lock-up expiry and unconfirmed orders, which is reasonable.
Three-tier value: Asset value (net cash) ~HK$3.47/share (55.3% of market cap, of which ~2/3 is IPO net proceeds with restricted use); EPV (zero-growth operating value) — insufficient inputs, not estimable — the company has no capitalizable sustainable positive operating cash flow (OCF negative in four of five years); using the historical-best adjusted net profit of RMB 25.7 million ÷ 10% cost of equity gives only ~HK$0.54/share and is not sustainable, so this report does not force a figure; therefore the ~HK$2.80/share (roughly 45% of market cap) above net cash at the current price is the entire consideration the market pays for growth and options — the growth component is not small, and the conclusion "the market pays only for zero growth" does not hold for this name; the crux is whether this option (NEURA + humanoid components + European channel) is worth HK$2.80.
Three scenarios and odds (12 months):
| Scenario | Probability | Fair range | vs Current | Crux |
|---|---|---|---|---|
| Bear | 0.33 | HK$4.6-5.6 | -27%~-11% | No European rebound in H2 (FY2026 revenue RMB 350-370 million, -4%~-10%), widening adjusted losses; compounded by lock-up expiry selling pressure. Stressed valuation: EV/S 2.0-2.8x × declining revenue + net cash (conservatively counted), ~HK$4.6-5.6; absolute floor = net cash HK$3.47/share |
| Base | 0.45 | HK$8.0-10.5 | +28%~+67% | Partial H2 rebound + first NEURA delivery recognition: FY2026 revenue RMB 420-480 million, FY2027 RMB 680-850 million, breakeven in 2027 (net profit attributable +RMB 40-90 million). Exit anchor 4.5-5.0x 2027E PS (BOCOM's self-set 5x sell-side anchor + HK peer PS-TTM 8.2-9.4x at a 50-60% discount) + net cash added back at ~60%, giving HK$8.5-11.0; conservative range HK$8.0-10.5 adopted |
| Bull | 0.22 | HK$13-18 | +107%~+187% | NEURA converting fully to formal orders + component revenue reaching RMB 400 million by 2027 + domestic humanoid customer order announcements + accelerated buyback ahead of lock-up expiry: FY2027 revenue RMB 1.1-1.3 billion, net profit attributable RMB 120-180 million. Exit anchor 4.5-6.0x 2027E PS (a steep discount to the A-share components chain at 56x PS, in line with HK complete-unit peers) |
Anchoring discipline note: exit multiples for the base/bull scenarios are independent of the company's current price (sell-side self-set anchor + median peer discount); the old September 2026 target prices (Deutsche Bank 28.2 / Citi 30.0) predate the halving of sector multiples and have not been updated — this report does not adopt them, and the bull-case ceiling is already at a steep discount to those. The current price sits between the bear and base cases, toward the lower end — odds are asymmetrically positive: ~+48% to base-case midpoint, ~-19% to bear-case midpoint; probability-weighted fair value ~HK$9.3 (~+48%). Bear-case external reference note: the most pessimistic available sell-side view is BOCOM (still Buy, HK$10.36); no sell-side supports bear-case levels; this bear case is constructed on independent stress assumptions and is not comparable to sell-side figures (whose 2027E already embeds the rebound).
House earnings forecast (reconciliation anchor):
| Period | Revenue | Net profit attributable | Key assumptions |
|---|---|---|---|
| FY2026 | RMB 420-480 million (~450) | -RMB 80~-35 million (~-60) | H2 European rebound to RMB 50-80 million + NEURA Q4 recognition of RMB 30-60 million; ASP declining 5-8% annually; gross margin 33-34%; FX gain of RMB 31.37 million already realized in H1 |
| FY2027 | RMB 650-850 million (~720) | +RMB 40-90 million (~+65) | NEURA annualized RMB 150-220 million (60-90% of the ~RMB 240 million framework average) + complete-unit base +15-20% + components/platforms RMB 120-180 million; gross margin 35-37% |
Comparison: Management gives no quantitative guidance (qualitative "rapid release in H2"); BOCOM 2026E revenue RMB 506 million / net profit attributable -RMB 82 million, 2027E +RMB 92 million — our 2026E revenue is ~11% below BOCOM and 2027E ~27% below (discounting the rebound magnitude and the 2027 ramp, based on Q4-2025 single-quarter revenue of only RMB 106 million indicating volatile recognition timing).
Conclusion: Undervalued (event-verification type) — Target price HK$8.0-10.5 (= base-case fair value), safety margin 27.6% (measured at base-case fair-value floor). Assess quality and price separately: quality is "qualified but with hard flaws" (genuine industry position + in-house components + net cash, hedging customer concentration/weak cash flow/governance related-party issues); the price carries a deep discount, but the discount has its reasons.
Industry Size: Collaborative robots are a high-growth sub-category within industrial robotics. Global market revenue in 2024 was approximately RMB 7.5 billion (Frost & Sullivan, cited in the Huayan prospectus), accounting for about 1.7% of the global robotics market; the China market was approximately RMB 2.2 billion in 2024. On shipments: under GGII's methodology, China's cobot (including four-axis) shipments in 2024 reached 40,000 units (+27.4%), the only industrial robot body category to achieve double-digit growth that year; in 2025, shipments further accelerated to 49,500 units (+45.59%). Growth forecasts must be assessed by methodology: Sullivan's forecast of a 2024-2029 global revenue CAGR of 37.4% (to RMB 35 billion) is an optimistic one; Interact Analysis (2025-07) forecasts a 2025-2029 global shipment CAGR of about 20%, but with revenue dragged down by 3-5% annual ARPU declines, putting 2029 revenue at only about USD 2.5 billion (a narrower methodology than Sullivan's). The judgment adopted in this report: a shipment CAGR of 20-30%, with revenue CAGR eroded by price wars to 10-20%, is a credible range—the divergence between the two third-party curves is itself a reflection of the industry's "volume up, price down" characteristic.
Structural Demand Inflection Point (Quantified Chain): The industry has two quantifiable demand chains. Chain One (quantified): cobot substitution of traditional industrial robots—China's industrial robot shipments in 2024 fell 4.5% (302,000 units) vs cobots up 27.4% (40,000 units), for a penetration rate of about 13.2%; Interact Analysis judges that substitution in high-precision assembly scenarios has reached a technical inflection point; under GGII's path, China's six-axis-and-above cobot shipments will exceed 110,000 units by 2028 (penetration rate 30%+). Chain Two (partially quantified, the core option in this report's target): exogenous demand for core motion components from humanoid robot industrialization—the trajectory of the key variable is China humanoid robot shipments of approximately 7,000-20,000 units in 2025 (wide divergence in methodology) → 162,500 units in 2030 (2025 China Humanoid Robot Industry Development Blue Book, implying a shipment CAGR of about 86%); unit usage is based on joint actuators accounting for roughly 45-70% of total humanoid robot cost (Morgan Stanley/Huatai estimates, with frameless motors, reducers, and torque sensors among the top four by value); the fourth link (Huayan's share of humanoid incremental demand) has no third-party benchmark—component revenue in 2026H1 was RMB 40.26 million, down 18.8% YoY, and the company itself describes the business as "still in small-batch production"; the only magnitude anchor is the NEURA framework order averaging approximately RMB 240 million per year (PR-basis). Conclusion: the first three links of the inflection chain are supported by third-party figures while the fourth is missing; this report does not assign a valuation premium directly on this narrative, but instead treats it as a scenario variable (bull-case component revenue reaching RMB 400 million in 2027), with order announcements serving as the validation trigger.
Value Chain and Value Distribution: Upstream core components (reducers/encoders/frameless torque motors/servo drives)—joint modules account for about 40-50% of cobot BOM (industry consensus, moderate reliability); midstream body manufacturing—heaviest squeeze from price wars; downstream system integration and process know-how—retains substantial gross margin (handling/assembly together account for 50%+ of global cobot revenue). Huayan sits in the dual segments of "body + core components": these are the two highest-margin segments of the value chain, and its differentiation lies in selling components from the same R&D platform to third parties (including humanoid customers), with component gross margins of 36.6%-53.9% exceeding the 35.2% for complete machines. Its bargaining power upstream is moderate-to-weak (top five suppliers account for 32.3% of cost of sales; dependence on outsourced reducers/encoders), and downstream bargaining power is weak (direct sales to integrators account for 86%; top five customers account for 60.6%).
Supply-Demand and Competitive Landscape: Loose supply, structurally tight demand. The global cobot market in 2024 was at the trough of this cycle (Interact Analysis called "rock bottom": 2023 shipments -14.3%, 2024 +13.8%), accelerating recovery from 2025 (+20.6%), peaking in 2026, then stabilizing. Competition in China is brutal: domestic brands hold over 90% of the China market (GGII, 2024 shipment basis); "the China price war is the main reason global revenue growth was <10% in 2024" (Interact Analysis); China ASP is expected to cumulatively decline over 10% from 2024 to 2029. Concentration: global CR5 on a revenue basis is 42.1% (Sullivan, 2024); China's landscape is more fragmented with no absolute leader. Entry barriers are medium-high (motion-control full-stack requires decade-scale accumulation, on-site industrial validation cycles, overseas CE certification, scale-based cost competition); substitution threats come from traditional smaller six-axis models moving down-market and, in the longer term, humanoids. Higher payloads are a structural tailwind (>10kg models' share rising from 25% in 2024 to 30%+ in 2029), corresponding to Huayan's S series (up to 60kg).
Cyclicality and Regulation: Cyclical position—mid-growth phase overlaid with a cyclical "trough recovery": China's industrial robot output in 2026-10 was up 26% YoY (National Bureau of Statistics), general industrial automation is on the upswing (Inovance 9M2026 general automation revenue +33%), but manufacturing PMI at 49.3 in 2026-10 fell back below the boom-bust line, indicating macro demand volatility. Regulation—domestically, policy is favorable: MIIT's Guidance on Innovative Development of Humanoid Robots (2023-11) set a 2027 mass-production target, and "embodied intelligence" was included in the Government Work Report for the first time in 2025; overseas, regulation is a marginal negative but exposure is small: the US 15% universal tariff (effective 2026-02, with Huayan's direct US-bound revenue at only about 1.2% and contracts stipulating customer absorption), the EU has already opened an anti-dumping case in an adjacent category (lawn-mowing robots), and the new Product Liability Directive (to be transposed before 2026-12) raises overseas compliance costs—an EU trade remedy case against collaborative robots would be a tail risk (European revenue in a normal year is on the order of RMB 100 million).
Peer Benchmarking:
| Company | Revenue Scale | Growth | Gross Margin | ROE/Profitability | Key Differences vs Huayan |
|---|---|---|---|---|---|
| Dobot (02432.HK) | 2025: RMB 492 million; 2026H1: RMB 316 million | 2025 +31.7%; 2026H1 +106.6% | 46-47% | Loss-making (2026H1 net loss RMB 108 million) | Most direct comparable: pure body maker + embodied AI transformation, light payloads + channels across 110 countries; Huayan focuses on heavy payloads + component sales + European industrial customers |
| UBTECH (09880.HK) | TTM approximately RMB 2.65 billion | 2026H1 +104.2% | — | Loss-making, OCF -RMB 750 million | Humanoid body precedent, market cap HKD 29.3 billion—a reference point for Hong Kong's willingness to pay 9x PS for the robotics narrative |
| Estun (002747.SZ) | 9M2025: RMB 3.8 billion | +13.0% | ~28.5% | Modest profit after heavy 2024 losses | Domestic leader in traditional six-axis/SCARA, more complementary than competing |
| Inovance (300124.SZ) | 2025: RMB 45.1 billion | +21.8% | 40.75% (segment) | Net profit attributable RMB 5.05 billion, net margin 11% | Industrial-automation platform giant, a potential substitute supply source for Huayan's component sales |
| JAKA Robotics (unlisted) | Not obtained | Not obtained | Not obtained | Not obtained | GGII shipment ranking No.1 (21.4%, 2025), excels in collaboration processes |
Company's Industry Position: Methodologies must be presented side by side—by revenue (Sullivan, 2024, commissioned for prospectus): No. 2 in China (10.3%), No. 5 globally (3.5%); by shipments (GGII, 2025): China's top five exclude Huayan (JAKA leads at 21.4%). The divergence stems from "revenue vs units, components included vs pure bodies," but the directional signal is consistent and cannot be ignored: industry shipments in 2025 grew +45.6% while company revenue grew +24.6%; in 2026H1 the industry grew strongly while the company stagnated—the company's share is likely being eroded. Independent corroboration: No. 2 on the 2025 China robotics overseas expansion ranking (GGII basis, FARO first). Overall judgment: a top challenger rather than the leader; moat lies in in-house components and European channels; share trend weakening in 2025-2026, pending H2 order validation.
The decisive factors in the robot body business are "volume × ASP × per-unit gross profit" and order recognition cadence; generic financial frameworks miss these layers:
Volume: E-series 9M2025 shipments of 2,556 units (9M2024: 1,906, +34%); S-series 808 units (+47% YoY... 9M2024 was 191)—volume is growing. Price: E-series ASP fell from 65,483 to 55,941 yuan (-14.6%); S-series from 82,729 to 56,388 yuan (-31.8%)—price is collapsing. The net effect of volume-price offset is 2025 revenue growth of +24.6% (9M2025 basis), significantly below shipment growth, while 2026H1 saw weakness in both volume and price compounded by Europe's absence, resulting in zero growth. Capacity utilization fell from 85.9% (2024) to 73.9% (2025, on annualized capacity of 5,269 units)—excess capacity and declining ASP reinforce each other; this is the industry price war projected directly onto the company's financials. Order cadence: the company's revenue recognition is heavily concentrated in H2 deliveries to major customers (Q4 2025 alone approximately RMB 106 million; management again stated in 2026 that "deployment is concentrated in the second half"), compounded by a 90-day credit policy—quarterly revenue volatility is high and predictability poor; extrapolations between quarterly reports are unreliable; only interim/annual results are hard validation points. The channel structure, with direct sales to integrators at 86%, means the company actually faces project-based intermediaries rather than end users, further discounting demand visibility.
Judgment: Cautiously bullish, confidence 0.55, time horizon 12 months. Huayan Robotics currently presents a "half cash position + event option" structure: net cash of HKD 3.47/share provides a floor, while option value of HKD 2.80/share depends on the NEURA order and humanoid component delivery. The three-scenario payoff is asymmetrically skewed positive (+28%~+67% to base case vs -27%~-11% to bear case), with probability-weighted fair value of approximately HKD 9.3; but directional conviction is constrained by three things—low evidentiary grade on orders (PR basis), approximately 51% of share capital unlocking in 2027-03 falling within the holding window, and no buffer in earnings/cash flow quality. Strategically: among the entry prerequisites, H2 backfill and orders converting to formal announcements are hard validations (2027-02 profit warning/annual report window); the share-unlock overhang can be considered partially cleared via hedging signals such as accelerated buybacks, extended lock-ups, or major-shareholder increases—the three items need not all be in place simultaneously, but heavy positioning is inadvisable before hard validation is passed; left-side buyers should use HKD 4.8 (near the bear-case floor) as the re-rating line and HKD 10.5 (base-case ceiling) as the margin-of-safety exhaustion line; position sizing should follow an "option" rather than a "value stock" framework.
Risks and Monitoring Points (presented in consistent formal language): ① Falsification risk—if the February 2027 profit warning shows H2 European revenue failed to backfill (full-year European revenue below RMB 50 million, i.e., H2 backfill of less than approximately RMB 33 million, significantly below 2025H1's RMB 50.4 million, and with no formal order announcement), thesis C2 collapses and valuation converges to the bear case; ② Shareholding-structure risk—around the 2027-03-30 unlock of the controlling-shareholder group, monitor Han's Laser or controlling-shareholder disclosure of interest changes, whether buybacks accelerate, and whether the Hang Seng Composite Index review (2027-02) maintains Stock Connect eligibility; ③ Quality risk—gross margin falling below 30, further significant inventory impairment, and renewed FX losses eroding earnings from RMB appreciation; ④ Upside validation—NEURA formal purchase order/first delivery announcement, domestic humanoid customer orders, and volume ramp of the precision platform on the Accelink/Innolight side.
Data and Methodology Disclosure: Financial data in this report are anchored on the accountants' report in the prospectus (2026-03-20) and the 2026 interim report. Due to a local PDF parsing pipeline failure, certain announcement details (FY2025 full-year operating cash flow, capex breakdown by year, top-five customer concentration for 2026H1) were obtained via third-party paraphrases (Gwun Fu / Futu / Gelonghui) or not obtained at all, and are marked with "—" in the tables; the NEURA framework order value is per the corporate press release and unconfirmed by exchange announcements; the unlock ratio is estimated from the CSRC full-circulation filing and the interim report shareholder table. These gaps do not change the directional conclusions, but investors should re-verify after the 2026 annual report is released.
(This report was generated by Loyan AI; price and valuation anchors are based on the 2026-11-20 HKEX closing price of HKD 6.27; it does not constitute investment advice.)
<!-- publication:e0d926c4541167d3113508a7 -->